Tumor-targeting peptides from combinatorial libraries

Advanced Drug Delivery Reviews

Volumn 110-111, Issue , 2017, Pages 13-37

  Liu, Ruiwu ^a,b   Li, Xiaocen ^a,b   Xiao, Wenwu ^a,b   Lam, Kit S ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Biological library; Cell surface receptor; High throughput screening; One bead one compound peptide library; Phage display peptide library; Tumor targeting peptide

Indexed keywords

CELL MEMBRANES; DIAGNOSIS; DISEASES; LIBRARIES; MOLECULAR IMAGING; TUMORS;

BINDING RECEPTORS; CELL SURFACE RECEPTORS; COMBINATORIAL LIBRARY; COMBINATORIAL LIBRARY METHOD; HIGH THROUGHPUT SCREENING; METASTATIC TUMORS; PEPTIDE LIBRARY; TUMOR TARGETING PEPTIDES;

PEPTIDES;

ALPHAVBETA3 INTEGRIN BINDING PEPTIDE DERIVATIVE; ALPHAVBETA6 INTEGRIN BINDING PEPTIDE DERIVATIVE; AMINOPEPTIDASE N BINDING PEPTIDE DERIVATIVE; ANTINEOPLASTIC AGENT; CILENGITIDE; CYTOTOXIC T LYMPHOCYTE-ASSOCIATED ANTIGEN 4 BINDING PEPTIDE DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR BINDING PEPTIDE DERIVATIVE; INTERLEUKIN 13 RECEPTOR ALPHA2 BINDING PEPTIDE DERIVATIVE; INTERLEUKIN 6 BINDING PEPTIDE DERIVATIVE; NEUROPILIN 1 BINDING PEPTIDE DERIVATIVE; OCTREOTIDE; PEPTIDE DERIVATIVE; PLATELET DERIVED GROWTH FACTOR RECEPTOR BETA BINDING PEPTIDE DERIVATIVE; PROTEIN TYROSINE PHOSPHATASE RECEPTOR TYPE J BINDING PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL GROWTH FACTOR BINDING PEPTIDE DERIVATIVE; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 BINDING PEPTIDE DERIVATIVE; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 3 BINDING PEPTIDE DERIVATIVE; VAV3 BINDING PEPTIDE DERIVATIVE; LIGAND; PEPTIDE; PROTEIN BINDING;

AMINO ACID SEQUENCE; BINDING AFFINITY; COMBINATORIAL LIBRARY; DRUG DELIVERY SYSTEM; GENE EXPRESSION PROFILING; GLIOBLASTOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IMMUNE RESPONSE; MELANOMA; METHODOLOGY; MICROARRAY ANALYSIS; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; STRUCTURE ACTIVITY RELATION; TUMOR XENOGRAFT; X RAY CRYSTALLOGRAPHY; ANIMAL; COMBINATORIAL CHEMISTRY; DIAGNOSTIC IMAGING; METABOLISM; NEOPLASM; PEPTIDE LIBRARY;

ANIMALS; COMBINATORIAL CHEMISTRY TECHNIQUES; HUMANS; LIGANDS; NEOPLASMS; PEPTIDE LIBRARY; PEPTIDES; PROTEIN BINDING;

EID: 85006414950     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2016.05.009     Document Type: Review

References (361)

1. Lopci, E., Nanni, C., Rampin, L., Rubello, D., Fanti, S., Clinical applications of 68Ga-DOTANOC in neuroendocrine tumours. Minerva Endocrinol. 33 (2008), 277–281.
2. Emons, G., Sindermann, H., Engel, J., Schally, A.V., Grundker, C., Luteinizing hormone-releasing hormone receptor-targeted chemotherapy using AN-152. Neuroendocrinology 90 (2009), 15–18.
3. Aina, O.H., Liu, R., Sutcliffe, J.L., Marik, J., Pan, C.X., Lam, K.S., From combinatorial chemistry to cancer-targeting peptides. Mol. Pharm. 4 (2007), 631–651.
4. Gray, B.P., Brown, K.C., Combinatorial peptide libraries: mining for cell-binding peptides. Chem. Rev. 114 (2014), 1020–1081.
5. Gautam, A., Kapoor, P., Chaudhary, K., Kumar, R., C. Open Source Drug Discovery, Raghava, G.P., Tumor homing peptides as molecular probes for cancer therapeutics, diagnostics and theranostics. Curr. Med. Chem. 21 (2014), 2367–2391.
6. Ullman, C.G., Frigotto, L., Cooley, R.N., In vitro methods for peptide display and their applications. Brief. Funct. Genomics 10 (2011), 125–134.
7. Williams, R.M., Sooter, L.J., In vitro selection of cancer cell-specific molecular recognition elements from amino acid libraries. J. Immunol. Res., 2015, 2015, 186586.
8. Cheetham, A.G., Keith, D., Zhang, P., Lin, R., Su, H., Cui, H., Targeting tumors with small molecule peptides. Curr. Cancer Drug Targets, 16, 2015, 10.2174/1568009616666151130214646 (Epub ahead of print).
9. Soudy, R., Byeon, N., Raghuwanshi, Y., Ahmed, S., Lavasanifar, A., Kaur, K., Engineered peptides for applications in cancer targeted drug delivery and tumor detection. Mini Rev. Med. Chem., 16, 2016, 10.2174/1389557516666160219121836 (Epub ahead of print).
10. Scott, J.K., Smith, G.P., Searching for peptide ligands with an epitope library. Science 249 (1990), 386–390.
11. Lam, K.S., Salmon, S.E., Hersh, E.M., Hruby, V.J., Kazmierski, W.M., Knapp, R.J., A new type of synthetic peptide library for identifying ligand-binding activity. Nature 354 (1991), 82–84.
12. Wolkowicz, R., Jager, G.C., Nolan, G.P., A random peptide library fused to CCR5 for selection of mimetopes expressed on the mammalian cell surface via retroviral vectors. J. Biol. Chem. 280 (2005), 15195–15201.
13. Kehoe, J.W., Kay, B.K., Filamentous phage display in the new millennium. Chem. Rev. 105 (2005), 4056–4072.
14. McLaughlin, M.E., Sidhu, S.S., Engineering and analysis of peptide-recognition domain specificities by phage display and deep sequencing. Methods Enzymol. 523 (2013), 327–349.
15. Kuzmicheva, G.A., Jayanna, P.K., Sorokulova, I.B., Petrenko, V.A., Diversity and censoring of landscape phage libraries. Protein Eng. Des. Sel. 22 (2009), 9–18.
16. Jafari, M.R., Deng, L., Kitov, P.I., Ng, S., Matochko, W.L., Tjhung, K.F., Zeberoff, A., Elias, A., Klassen, J.S., Derda, R., Discovery of light-responsive ligands through screening of a light-responsive genetically encoded library. ACS Chem. Biol. 9 (2014), 443–450.
17. Chen, S., Touati, J., Heinis, C., Tracking chemical reactions on the surface of filamentous phage using mass spectrometry. Chem. Commun. (Camb.) 50 (2014), 5267–5269.
18. Heinis, C., Rutherford, T., Freund, S., Winter, G., Phage-encoded combinatorial chemical libraries based on bicyclic peptides. Nat. Chem. Biol. 5 (2009), 502–507.
19. Kay, B.K., Kasanov, J., Yamabhai, M., Screening phage-displayed combinatorial peptide libraries. Methods 24 (2001), 240–246.
20. McGuire, M.J., Samli, K.N., Chang, Y.C., Brown, K.C., Novel ligands for cancer diagnosis: selection of peptide ligands for identification and isolation of B-cell lymphomas. Exp. Hematol. 34 (2006), 443–452.
21. Li, Z., Zhao, R., Wu, X., Sun, Y., Yao, M., Li, J., Xu, Y., Gu, J., Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics. FASEB J. 19 (2005), 1978–1985.
22. Hamzeh-Mivehroud, M., Mahmoudpour, A., Dastmalchi, S., Identification of new peptide ligands for epidermal growth factor receptor using phage display and computationally modeling their mode of binding. Chem. Biol. Drug Des. 79 (2012), 246–259.
23. Desgrosellier, J.S., Cheresh, D.A., Integrins in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer 10 (2010), 9–22.
24. Elayadi, A.N., Samli, K.N., Prudkin, L., Liu, Y.H., Bian, A., Xie, X.J., Wistuba, I.I., Roth, J.A., McGuire, M.J., Brown, K.C., A peptide selected by biopanning identifies the integrin alphavbeta6 as a prognostic biomarker for nonsmall cell lung cancer. Cancer Res. 67 (2007), 5889–5895.
25. Oyama, T., Sykes, K.F., Samli, K.N., Minna, J.D., Johnston, S.A., Brown, K.C., Isolation of lung tumor specific peptides from a random peptide library: generation of diagnostic and cell-targeting reagents. Cancer Lett. 202 (2003), 219–230.
26. Nothelfer, E.M., Zitzmann-Kolbe, S., Garcia-Boy, R., Kramer, S., Herold-Mende, C., Altmann, A., Eisenhut, M., Mier, W., Haberkorn, U., Identification and characterization of a peptide with affinity to head and neck cancer. J. Nucl. Med. 50 (2009), 426–434.
27. Kraft, S., Diefenbach, B., Mehta, R., Jonczyk, A., Luckenbach, G.A., Goodman, S.L., Definition of an unexpected ligand recognition motif for alphav beta6 integrin. J. Biol. Chem. 274 (1999), 1979–1985.
28. Kimura, R.H., Teed, R., Hackel, B.J., Pysz, M.A., Chuang, C.Z., Sathirachinda, A., Willmann, J.K., Gambhir, S.S., Pharmacokinetically stabilized cystine knot peptides that bind alpha-v-beta-6 integrin with single-digit nanomolar affinities for detection of pancreatic cancer. Clin. Cancer Res. 18 (2012), 839–849.
29. Liu, H., Wu, Y., Wang, F., Liu, Z., Molecular imaging of integrin alphavbeta6 expression in living subjects. Am. J. Nucl. Med. Mol. Imaging 4 (2014), 333–345.
30. Gu, C., Rodriguez, E.R., Reimert, D.V., Shu, T., Fritzsch, B., Richards, L.J., Kolodkin, A.L., Ginty, D.D., Neuropilin-1 conveys semaphorin and VEGF signaling during neural and cardiovascular development. Dev. Cell 5 (2003), 45–57.
31. Herzog, Y., Kalcheim, C., Kahane, N., Reshef, R., Neufeld, G., Differential expression of neuropilin-1 and neuropilin-2 in arteries and veins. Mech. Dev. 109 (2001), 115–119.
32. Tordjman, R., Lepelletier, Y., Lemarchandel, V., Cambot, M., Gaulard, P., Hermine, O., Romeo, P.H., A neuronal receptor, neuropilin-1, is essential for the initiation of the primary immune response. Nat. Immunol. 3 (2002), 477–482.
33. Matthies, A.M., Low, Q.E., Lingen, M.W., DiPietro, L.A., Neuropilin-1 participates in wound angiogenesis. Am. J. Pathol. 160 (2002), 289–296.
34. Klagsbrun, M., Takashima, S., Mamluk, R., The role of neuropilin in vascular and tumor biology. Adv. Exp. Med. Biol. 515 (2002), 33–48.
35. Karjalainen, K., Jaalouk, D.E., Bueso-Ramos, C.E., Zurita, A.J., Kuniyasu, A., Eckhardt, B.L., Marini, F.C., Lichtiger, B., O'Brien, S., Kantarjian, H.M., Cortes, J.E., Koivunen, E., Arap, W., Pasqualini, R., Targeting neuropilin-1 in human leukemia and lymphoma. Blood 117 (2011), 920–927.
36. Kreuter, M., Woelke, K., Bieker, R., Schliemann, C., Steins, M., Buechner, T., Berdel, W.E., Mesters, R.M., Correlation of neuropilin-1 overexpression to survival in acute myeloid leukemia. Leukemia 20 (2006), 1950–1954.
37. Teesalu, T., Sugahara, K.N., Kotamraju, V.R., Ruoslahti, E., C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 16157–16162.
38. Wang, J., Liu, Y., Teesalu, T., Sugahara, K.N., Kotamrajua, V.R., Adams, J.D., Ferguson, B.S., Gong, Q., Oh, S.S., Csordas, A.T., Cho, M., Ruoslahti, E., Xiao, Y., Soh, H.T., Selection of phage-displayed peptides on live adherent cells in microfluidic channels. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 6909–6914 (S6909/6901-S6909/6905).
39. Jin, H., Varner, J., Integrins: roles in cancer development and as treatment targets. Br. J. Cancer 90 (2004), 561–565.
40. Koivunen, E., Wang, B., Ruoslahti, E., Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins. Biotechnology (N Y) 13 (1995), 265–270.
41. Witt, H., Hajdin, K., Iljin, K., Greiner, O., Niggli, F.K., Schafer, B.W., Bernasconi, M., Identification of a rhabdomyosarcoma targeting peptide by phage display with sequence similarities to the tumour lymphatic-homing peptide LyP-1. Int. J. Cancer 124 (2009), 2026–2032.
42. Sugahara, K.N., Teesalu, T., Karmali, P.P., Kotamraju, V.R., Agemy, L., Girard, O.M., Hanahan, D., Mattrey, R.F., Ruoslahti, E., Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell 16 (2009), 510–520.
43. Kessler, R.G.H., Hessler, G., Gurrath, M., Muller, G., Conformation of cyclic peptides. Principle concepts and the design of selectivity and superactivity in bioactive sequences by spatial screening'. Pure Appl. Chem., 68, 1996, 5.
44. Haubner, R., Gratias, R., Diefenbach, B., Goodman, S.L., Jonczyk, A., Kessler, H., Structural and functional aspects of RGD-containing cyclic pentapeptides as highly potent and selective integrin αvβ3 antagonists. J. Am. Chem. Soc., 118, 1996, 13.
45. Dechantsreiter, M.A., Planker, E., Matha, B., Lohof, E., Holzemann, G., Jonczyk, A., Goodman, S.L., Kessler, H., N-methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists. J. Med. Chem. 42 (1999), 3033–3040.
46. Yamada, S., Bu, X.Y., Khankaldyyan, V., Gonzales-Gomez, I., McComb, J.G., Laug, W.E., Effect of the angiogenesis inhibitor Cilengitide (EMD 121974) on glioblastoma growth in nude mice. Neurosurgery 59 (2006), 1304–1312 (discussion 1312).
47. Reardon, D.A., Fink, K.L., Mikkelsen, T., Cloughesy, T.F., O'Neill, A., Plotkin, S., Glantz, M., Ravin, P., Raizer, J.J., Rich, K.M., Schiff, D., Shapiro, W.R., Burdette-Radoux, S., Dropcho, E.J., Wittemer, S.M., Nippgen, J., Picard, M., Nabors, L.B., Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J. Clin. Oncol. 26 (2008), 5610–5617.
48. Stupp, R., Hegi, M.E., Gorlia, T., Erridge, S.C., Perry, J., Hong, Y.K., Aldape, K.D., Lhermitte, B., Pietsch, T., Grujicic, D., Steinbach, J.P., Wick, W., Tarnawski, R., Nam, D.H., Hau, P., Weyerbrock, A., Taphoorn, M.J., Shen, C.C., Rao, N., Thurzo, L., Herrlinger, U., Gupta, T., Kortmann, R.D., Adamska, K., McBain, C., Brandes, A.A., Tonn, J.C., Schnell, O., Wiegel, T., Kim, C.Y., Nabors, L.B., Reardon, D.A., van den Bent, M.J., Hicking, C., Markivskyy, A., Picard, M., Weller, M., R. European Organisation for, C. Treatment of, C. Canadian Brain Tumor, C.s. team, Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 15 (2014), 1100–1108.
49. Wykosky, J., Gibo, D.M., Stanton, C., Debinski, W., Interleukin-13 receptor alpha 2, EphA2, and Fos-related antigen 1 as molecular denominators of high-grade astrocytomas and specific targets for combinatorial therapy. Clin. Cancer Res. 14 (2008), 199–208.
50. Pandya, H., Gibo, D.M., Garg, S., Kridel, S., Debinski, W., An interleukin 13 receptor α 2-specific peptide homes to human glioblastoma multiforme xenografts. Neuro-Oncology 14 (2012), 6–18.
51. Kubo, H., Cao, R., Brakenhielm, E., Makinen, T., Cao, Y., Alitalo, K., Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibroblast growth factor-2-induced lymphangiogenesis in mouse cornea. Proc. Natl. Acad. Sci. U. S. A. 99 (2002), 8868–8873.
52. Laakkonen, P., Waltari, M., Holopainen, T., Takahashi, T., Pytowski, B., Steiner, P., Hicklin, D., Persaud, K., Tonra, J.R., Witte, L., Alitalo, K., Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth. Cancer Res. 67 (2007), 593–599.
53. Qin, X., Wan, Y., Li, M., Xue, X., Wu, S., Zhang, C., You, Y., Wang, W., Jiang, C., Liu, Y., Zhu, W., Ran, Y., Zhang, Z., Han, W., Zhang, Y., Identification of a novel peptide ligand of human vascular endothelia growth factor receptor 3 for targeted tumor diagnosis and therapy. J. Biochem. 142 (2007), 79–85.
54. Pietras, K., Rubin, K., Sjoblom, T., Buchdunger, E., Sjoquist, M., Heldin, C.H., Ostman, A., Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res. 62 (2002), 5476–5484.
55. Askoxylakis, V., Marr, A., Altmann, A., Markert, A., Mier, W., Debus, J., Huber, P.E., Haberkorn, U., Peptide-based targeting of the platelet-derived growth factor receptor beta. Mol. Imaging Biol. 15 (2013), 212–221.
56. Blume-Jensen, P., Hunter, T., Oncogenic kinase signalling. Nature 411 (2001), 355–365.
57. Zhang, J.M., Yang, P.L., Gray, N.S., Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer 9 (2009), 28–39.
58. Ostman, A., Hellberg, C., Bohmer, F.D., Protein-tyrosine phosphatases and cancer. Nat. Rev. Cancer 6 (2006), 307–320.
59. Paduano, F., Ortuso, F., Campiglia, P., Raso, C., Iaccino, E., Gaspari, M., Gaudio, E., Mangone, G., Carotenuto, A., Bilotta, A., Narciso, D., Palmieri, C., Agosti, V., Artese, A., Gomez-Monterrey, I., Sala, M., Cuda, G., Iuliano, R., Perrotti, N., Scala, G., Viglietto, G., Alcaro, S., Croce, C.M., Novellino, E., Fusco, A., Trapasso, F., Isolation and functional characterization of peptide agonists of PTPRJ, a tyrosine phosphatase receptor endowed with tumor suppressor activity. ACS Chem. Biol. 7 (2012), 1666–1676.
60. Ortuso, F., Paduano, F., Carotenuto, A., Gomez-Monterrey, I., Bilotta, A., Gaudio, E., Sala, M., Artese, A., Vernieri, E., Dattilo, V., Iuliano, R., Brancaccio, D., Bertamino, A., Musella, S., Alcaro, S., Grieco, P., Perrotti, N., Croce, C.M., Novellino, E., Fusco, A., Campiglia, P., Trapasso, F., Discovery of PTPRJ agonist peptides that effectively inhibit in vitro cancer cell proliferation and tube formation. ACS Chem. Biol. 8 (2013), 1497–1506.
61. Liu, J.K., Lubelski, D., Schonberg, D.L., Wu, Q., Hale, J.S., Flavahan, W.A., Mulkearns-Hubert, E.E., Man, J., Hjelmeland, A.B., Yu, J., Lathia, J.D., Rich, J.N., Phage display discovery of novel molecular targets in glioblastoma-initiating cells. Cell Death Differ. 21 (2014), 1325–1339.
62. Boder, E.T., Wittrup, K.D., Yeast surface display for screening combinatorial polypeptide libraries. Nat. Biotechnol. 15 (1997), 553–557.
63. Angelini, A., Chen, T.F., de Picciotto, S., Yang, N.J., Tzeng, A., Santos, M.S., Van Deventer, J.A., Traxlmayr, M.W., Wittrup, K.D., Protein engineering and selection using yeast surface display. Methods Mol. Biol. 1319 (2015), 3–36.
64. Gera, N., Hussain, M., Rao, B.M., Protein selection using yeast surface display. Methods 60 (2013), 15–26.
65. Silverman, A.P., Levin, A.M., Lahti, J.L., Cochran, J.R., Engineered cystine-knot peptides that bind alpha(v)beta(3) integrin with antibody-like affinities. J. Mol. Biol. 385 (2009), 1064–1075.
66. Kolmar, H., Alternative binding proteins: biological activity and therapeutic potential of cystine-knot miniproteins. FEBS J. 275 (2008), 2684–2690.
67. Maass, F., Wustehube-Lausch, J., Dickgiessr, S., Valldorf, B., Reinwarth, M., Schmoldt, H.U., Daneschdar, M., Avrutina, O., Sahin, U., Kolmar, H., Cystine-knot peptides targeting cancer-relevant human cytotoxic T lymphocyte-associated antigen 4 (CTLA-4). J. Pept. Sci. 21 (2015), 651–660.
68. Freudl, R., MacIntyre, S., Degen, M., Henning, U., Cell surface exposure of the outer membrane protein OmpA of Escherichia coli K-12. J. Mol. Biol. 188 (1986), 491–494.
69. Lunder, M., Bratkovic, T., Doljak, B., Kreft, S., Urleb, U., Strukelj, B., Plazar, N., Comparison of bacterial and phage display peptide libraries in search of target-binding motif. Appl. Biochem. Biotechnol. 127 (2005), 125–131.
70. Getz, J.A., Schoep, T.D., Daugherty, P.S., Peptide Discovery Using Bacterial Display and Flow Cytometry. 2012.
71. Daugherty, P.S., Protein engineering with bacterial display. Curr. Opin. Struct. Biol. 17 (2007), 474–480.
72. Lee, S.Y., Choi, J.H., Xu, Z., Microbial cell-surface display. Trends Biotechnol. 21 (2003), 45–52.
73. Jostock, T., Dubel, S., Screening of molecular repertoires by microbial surface display. Comb. Chem. High Throughput Screen. 8 (2005), 127–133.
74. Getz, J.A., Schoep, T.D., Daugherty, P.S., Peptide discovery using bacterial display and flow cytometry. Methods Enzymol. 503 (2012), 75–97.
75. Bessette, P.H., Rice, J.J., Daugherty, P.S., Rapid isolation of high-affinity protein binding peptides using bacterial display. Protein Eng. Des. Sel. 17 (2004), 731–739.
76. Kenrick, S.A., Daugherty, P.S., Bacterial display enables efficient and quantitative peptide affinity maturation. Protein Eng. Des. Sel. 23 (2010), 9–17.
77. Goel, H.L., Mercurio, A.M., VEGF targets the tumour cell. Nat. Rev. Cancer 13 (2013), 871–882.
78. Zahnd, C., Amstutz, P., Pluckthun, A., Ribosome display: selecting and evolving proteins in vitro that specifically bind to a target. Nat. Methods 4 (2007), 269–279.
79. Hara, S., Liu, M.Z., Wang, W., Xu, M.Y., Li, Z., Ito, Y., Stabilized ribosome display for in vitro selection. Methods Mol. Biol. 805 (2012), 59–73.
80. Kawasaki, G., Screening Randomized Peptides and Proteins With Polysomes, PCT Int. Appl. WO 91/05058. 1991.
81. Mattheakis, L.C., Bhatt, R.R., Dower, W.J., An in vitro polysome display system for identifying ligands from very large peptide libraries. Proc. Natl. Acad. Sci. U. S. A. 91 (1994), 9022–9026.
82. Heyduk, E., Heyduk, T., Ribosome display enhanced by next generation sequencing: a tool to identify antibody-specific peptide ligands. Anal. Biochem. 464 (2014), 73–82.
83. Pluckthun, A., Ribosome display: a perspective. Methods Mol. Biol. 805 (2012), 3–28.
84. Josephson, K., Ricardo, A., Szostak, J.W., mRNA display: from basic principles to macrocycle drug discovery. Drug Discov. Today 19 (2014), 388–399.
85. Wen, Z.S., Rong, T.H., Establishment of tumor cell membrane model and screening for specific anti-tumor peptides. Ai Zheng 23 (2004), 1660–1665.
86. Guo, Y., Xu, F., Lu, T., Duan, Z., Zhang, Z., Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat. Rev. 38 (2012), 904–910.
87. Waldner, M.J., Foersch, S., Neurath, M.F., Interleukin-6—a key regulator of colorectal cancer development. Int. J. Biol. Sci. 8 (2012), 1248–1253.
88. Schafer, Z.T., Brugge, J.S., IL-6 involvement in epithelial cancers. J. Clin. Invest. 117 (2007), 3660–3663.
89. Kobayashi, T., Kakui, M., Shibui, T., Kitano, Y., In vitro selection of a peptide inhibitor of human IL-6 using mRNA display. Mol. Biotechnol. 48 (2011), 147–155.
90. Kawakami, T., Ishizawa, T., Fujino, T., Reid, P.C., Suga, H., Murakami, H., In vitro selection of multiple libraries created by genetic code reprogramming to discover macrocyclic peptides that antagonize VEGFR2 activity in living cells. ACS Chem. Biol. 8 (2013), 1205–1214.
91. Udugamasooriya, D.G., Dunham, G., Ritchie, C., Brekken, R.A., Kodadek, T., The pharmacophore of a peptoid VEGF receptor 2 antagonist includes both side chain and main chain residues. Bioorg. Med. Chem. Lett. 18 (2008), 5892–5894.
92. Udugamasooriya, D.G., Ritchie, C., Brekken, R.A., Kodadek, T., A peptoid antagonist of VEGF receptor 2 recognizes a ‘hotspot’ in the extracellular domain distinct from the hormone-binding site. Bioorg. Med. Chem. 16 (2008), 6338–6343.
93. Shrivastava, A., von Wronski, M.A., Sato, A.K., Dransfield, D.T., Sexton, D., Bogdan, N., Pillai, R., Nanjappan, P., Song, B., Marinelli, E., DeOliveira, D., Luneau, C., Devlin, M., Muruganandam, A., Abujoub, A., Connelly, G., Wu, Q.L., Conley, G., Chang, Q., Tweedle, M.F., Ladner, R.C., Swenson, R.E., Nunn, A.D., A distinct strategy to generate high-affinity peptide binders to receptor tyrosine kinases. Protein Eng. Des. Sel. 18 (2005), 417–424.
94. Lam, K.S., Lehman, A.L., Song, A., Doan, N., Enstrom, A.M., Maxwell, J., Liu, R., Synthesis and screening of “one-bead one-compound” combinatorial peptide libraries. Methods Enzymol. 369 (2003), 298–322.
95. Wang, X., Peng, L., Liu, R., Xu, B., Lam, K.S., Applications of topologically segregated bilayer beads in ‘one-bead one-compound’ combinatorial libraries. J. Pept. Res. 65 (2005), 130–138.
96. Chen, X., Tan, P.H., Zhang, Y., Pei, D., On-bead screening of combinatorial libraries: reduction of nonspecific binding by decreasing surface ligand density. J. Comb. Chem. 11 (2009), 604–611.
97. Liu, R., Marik, J., Lam, K.S., A novel peptide-based encoding system for “one-bead one-compound” peptidomimetic and small molecule combinatorial libraries. J. Am. Chem. Soc. 124 (2002), 7678–7680.
98. Doran, T.M., Gao, Y., Mendes, K., Dean, S., Simanski, S., Kodadek, T., Utility of redundant combinatorial libraries in distinguishing high and low quality screening hits. ACS Comb. Sci. 16 (2014), 259–270.
99. Hintersteiner, M., Kimmerlin, T., Kalthoff, F., Stoeckli, M., Garavel, G., Seifert, J.M., Meisner, N.C., Uhl, V., Buehler, C., Weidemann, T., Auer, M., Single bead labeling method for combining confocal fluorescence on-bead screening and solution validation of tagged one-bead one-compound libraries. Chem. Biol. 16 (2009), 724–735.
100. Astle, J.M., Simpson, L.S., Huang, Y., Reddy, M.M., Wilson, R., Connell, S., Wilson, J., Kodadek, T., Seamless bead to microarray screening: rapid identification of the highest affinity protein ligands from large combinatorial libraries. Chem. Biol. 17 (2010), 38–45.
101. Mendes, K., Ndungu, J.M., Clark, L.F., Kodadek, T., Optimization of the magnetic recovery of hits from one-bead-one-compound library screens. ACS Comb. Sci. 17 (2015), 506–517.
102. Liu, R., Lam, K.S., Automatic Edman microsequencing of peptides containing multiple unnatural amino acids. Anal. Biochem. 295 (2001), 9–16.
103. Paulick, M.G., Hart, K.M., Brinner, K.M., Tjandra, M., Charych, D.H., Zuckermann, R.N., Cleavable hydrophilic linker for one-bead-one-compound sequencing of oligomer libraries by tandem mass spectrometry. J. Comb. Chem. 8 (2006), 417–426.
104. Joo, S.H., Xiao, Q., Ling, Y., Gopishetty, B., Pei, D., High-throughput sequence determination of cyclic peptide library members by partial Edman degradation/mass spectrometry. J. Am. Chem. Soc. 128 (2006), 13000–13009.
105. Townsend, J.B., Shaheen, F., Liu, R., Lam, K.S., Jeffamine derivatized TentaGel beads and poly(dimethylsiloxane) microbead cassettes for ultrahigh-throughput in situ releasable solution-phase cell-based screening of one-bead-one-compound combinatorial small molecule libraries. J. Comb. Chem. 12 (2010), 700–712.
106. Kumaresan, P.R., Wang, Y., Saunders, M., Maeda, Y., Liu, R., Wang, X., Lam, K.S., Rapid discovery of death ligands with one-bead-two-compound combinatorial library methods. ACS Comb. Sci. 13 (2011), 259–264.
107. Liu, R., Shih, T.C., Deng, X., Anwar, L., Ahadi, S., Kumaresan, P., Lam, K.S., Design, synthesis, and application of OB2C combinatorial peptide and peptidomimetic libraries. Methods Mol. Biol. 1248 (2015), 3–22.
108. Wang, Y., Xiao, W., Zhang, Y., Meza, L., Tseng, H., Takada, Y., Ames, J.B., Lam, K.S., Optimization of RGD containing cyclic peptides against alphavbeta3 integrin. Mol. Cancer Ther. 15 (2016), 232–240.
109. Kracun, S.K., Clo, E., Clausen, H., Levery, S.B., Jensen, K.J., Blixt, O., Random glycopeptide bead libraries for seromic biomarker discovery. J. Proteome Res. 9 (2010), 6705–6714.
110. Clo, E., Kracun, S.K., Nudelman, A.S., Jensen, K.J., Liljeqvist, J.A., Olofsson, S., Bergstrom, T., Blixt, O., Characterization of the viral O-glycopeptidome: a novel tool of relevance for vaccine design and serodiagnosis. J. Virol. 86 (2012), 6268–6278.
111. Ying, L., Liu, R., Zhang, J., Lam, K., Lebrilla, C.B., Gervay-Hague, J., A topologically segregated one-bead-one-compound combinatorial glycopeptide library for identification of lectin ligands. J. Comb. Chem. 7 (2005), 372–384.
112. Gao, Y., Kodadek, T., Split-and-pool synthesis and characterization of peptide tertiary amide library. J. Vis. Exp., 88, 2014, e51299.
113. Pels, K., Kodadek, T., Solid-phase synthesis of diverse peptide tertiary amides by reductive amination. ACS Comb. Sci. 17 (2015), 152–155.
114. Teng, P., Zhang, X., Wu, H., Qiao, Q., Sebti, S.M., Cai, J., Identification of novel inhibitors that disrupt STAT3–DNA interaction from a gamma-AApeptide OBOC combinatorial library. Chem. Commun. (Camb.) 50 (2014), 8739–8742.
115. Peng, L., Liu, R., Marik, J., Wang, X., Takada, Y., Lam, K.S., Combinatorial chemistry identifies high-affinity peptidomimetics against alpha4beta1 integrin for in vivo tumor imaging. Nat. Chem. Biol. 2 (2006), 381–389.
116. Qi, X., Astle, J., Kodadek, T., Rapid identification of orexin receptor binding ligands using cell-based screening accelerated with magnetic beads. Mol. BioSyst. 6 (2010), 102–107.
117. Lehman, A., Gholami, S., Hahn, M., Lam, K.S., Image subtraction approach to screening one-bead-one-compound combinatorial libraries with complex protein mixtures. J. Comb. Chem. 8 (2006), 562–570.
118. Cho, C.F., Behnam Azad, B., Luyt, L.G., Lewis, J.D., High-throughput screening of one-bead-one-compound peptide libraries using intact cells. ACS Comb. Sci. 15 (2013), 393–400.
119. Townsend, J., Do, A., Lehman, A., Dixon, S., Sanii, B., Lam, K.S., 3-Nitro-tyrosine as an internal quencher of autofluorescence enhances the compatibility of fluorescence based screening of OBOC combinatorial libraries. Comb. Chem. High Throughput Screen. 13 (2010), 422–429.
120. Paulus, W., Baur, I., Schuppan, D., Roggendorf, W., Characterization of integrin receptors in normal and neoplastic human brain. Am. J. Pathol. 143 (1993), 154–163.
121. Xiao, K., Li, Y., Lee, J.S., Gonik, A.M., Dong, T., Fung, G., Sanchez, E., Xing, L., Cheng, H.R., Luo, J., Lam, K.S., “OA02” peptide facilitates the precise targeting of paclitaxel-loaded micellar nanoparticles to ovarian cancer in vivo. Cancer Res. 72 (2012), 2100–2110.
122. Coopman, P.J., Thomas, D.M., Gehlsen, K.R., Mueller, S.C., Integrin alpha 3 beta 1 participates in the phagocytosis of extracellular matrix molecules by human breast cancer cells. Mol. Biol. Cell 7 (1996), 1789–1804.
123. Patriarca, C., Ivanyi, D., Fles, D., de Melker, A., van Doornewaard, G., Oomen, L., Alfano, R.M., Coggi, G., Sonnenberg, A., Distribution of extracellular and cytoplasmic domains of the alpha 3 and alpha 6 integrin subunits in solid tumors. Int. J. Cancer 63 (1995), 182–189.
124. Morini, M., Mottolese, M., Ferrari, N., Ghiorzo, F., Buglioni, S., Mortarini, R., Noonan, D.M., Natali, P.G., Albini, A., The alpha 3 beta 1 integrin is associated with mammary carcinoma cell metastasis, invasion, and gelatinase B (MMP-9) activity. Int. J. Cancer 87 (2000), 336–342.
125. Gogali, A., Charalabopoulos, K., Constantopoulos, S., Integrin receptors in primary lung cancer. Exp. Oncol. 26 (2004), 106–110.
126. Mizejewski, G.J., Role of integrins in cancer: survey of expression patterns. Proc. Soc. Exp. Biol. Med. 222 (1999), 124–138.
127. Takenaka, K., Shibuya, M., Takeda, Y., Hibino, S., Gemma, A., Ono, Y., Kudoh, S., Altered expression and function of beta1 integrins in a highly metastatic human lung adenocarcinoma cell line. Int. J. Oncol. 17 (2000), 1187–1194.
128. Varzavand, A., Drake, J.M., Svensson, R.U., Herndon, M.E., Zhou, B., Henry, M.D., Stipp, C.S., Integrin alpha3beta1 regulates tumor cell responses to stromal cells and can function to suppress prostate cancer metastatic colonization. Clin. Exp. Metastasis 30 (2013), 541–552.
129. Yoshimasu, T., Sakurai, T., Oura, S., Hirai, I., Tanino, H., Kokawa, Y., Naito, Y., Okamura, Y., Ota, I., Tani, N., Matsuura, N., Increased expression of integrin alpha3beta1 in highly brain metastatic subclone of a human non-small cell lung cancer cell line. Cancer Sci. 95 (2004), 142–148.
130. Zhou, B., Gibson-Corley, K.N., Herndon, M.E., Sun, Y., Gustafson-Wagner, E., Teoh-Fitzgerald, M., Domann, F.E., Henry, M.D., Stipp, C.S., Integrin alpha3beta1 can function to promote spontaneous metastasis and lung colonization of invasive breast carcinoma. Mol. Cancer Res. 12 (2014), 143–154.
131. Aina, O.H., Marik, J., Gandour-Edwards, R., Lam, K.S., Near-infrared optical imaging of ovarian cancer xenografts with novel alpha 3-integrin binding peptide “OA02”. Mol. Imaging 4 (2005), 439–447.
132. Xiao, W., Yao, N., Peng, L., Liu, R., Lam, K.S., Near-infrared optical imaging in glioblastoma xenograft with ligand-targeting alpha 3 integrin. Eur. J. Nucl. Med. Mol. Imaging 36 (2009), 94–103.
133. Yao, N., Xiao, W., Wang, X., Marik, J., Park, S.H., Takada, Y., Lam, K.S., Discovery of targeting ligands for breast cancer cells using the one-bead one-compound combinatorial method. J. Med. Chem. 52 (2009), 126–133.
134. Xiao, W., Li, T., Bononi, F., Lac, D., Kekessie, I., Liu, Y., Sanchez, E., Mazloom, A., Ma, A.-H., Lin, J., Tran, J., Yang, K., Lam, K., Liu, R., Discovery and characterization of a high affinity and specificity peptide ligand LXY30 for in vivo targeting of α3 integrin-expressing human tumors. EJNMMI Res., 6, 2016, 18.
135. Osborn, L., Vassallo, C., Browning, B.G., Tizard, R., Haskard, D.O., Benjamin, C.D., Dougas, I., Kirchhausen, T., Arrangement of domains, and amino acid residues required for binding of vascular cell adhesion molecule-1 to its counter-receptor VLA-4 (alpha 4 beta 1). J. Cell Biol. 124 (1994), 601–608.
136. Komoriya, A., Green, L.J., Mervic, M., Yamada, S.S., Yamada, K.M., Humphries, M.J., The minimal essential sequence for a major cell type-specific adhesion site (CS1) within the alternatively spliced type III connecting segment domain of fibronectin is leucine-aspartic acid-valine. J. Biol. Chem. 266 (1991), 15075–15079.
137. Holzmann, B., Gosslar, U., Bittner, M., Alpha 4 integrins and tumor metastasis. Curr. Top. Microbiol. Immunol. 231 (1998), 125–141.
138. Till, K.J., Lin, K., Zuzel, M., Cawley, J.C., The chemokine receptor CCR7 and alpha4 integrin are important for migration of chronic lymphocytic leukemia cells into lymph nodes. Blood 99 (2002), 2977–2984.
139. Vincent, A.M., Cawley, J.C., Burthem, J., Integrin function in chronic lymphocytic leukemia. Blood 87 (1996), 4780–4788.
140. de la Fuente, M.T., Casanova, B., Garcia-Gila, M., Silva, A., Garcia-Pardo, A., Fibronectin interaction with alpha4beta1 integrin prevents apoptosis in B cell chronic lymphocytic leukemia: correlation with Bcl-2 and Bax. Leukemia 13 (1999), 266–274.
141. Damiano, J.S., Dalton, W.S., Integrin-mediated drug resistance in multiple myeloma. Leuk. Lymphoma 38 (2000), 71–81.
142. Matsunaga, T., Takemoto, N., Sato, T., Takimoto, R., Tanaka, I., Fujimi, A., Akiyama, T., Kuroda, H., Kawano, Y., Kobune, M., Kato, J., Hirayama, Y., Sakamaki, S., Kohda, K., Miyake, K., Niitsu, Y., Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat. Med. 9 (2003), 1158–1165.
143. Olson, D.L., Burkly, L.C., Leone, D.R., Dolinski, B.M., Lobb, R.R., Anti-alpha4 integrin monoclonal antibody inhibits multiple myeloma growth in a murine model. Mol. Cancer Ther. 4 (2005), 91–99.
144. Garmy-Susini, B., Jin, H., Zhu, Y., Sung, R.J., Hwang, R., Varner, J., Integrin alpha4beta1-VCAM-1-mediated adhesion between endothelial and mural cells is required for blood vessel maturation. J. Clin. Invest. 115 (2005), 1542–1551.
145. Park, S.I., Manat, R., Vikstrom, B., Amro, N., Song, L.W., Lam, K.S., The use of one-bead one-compound combinatorial library method to identify peptide ligands for alpha-4-beta-1 integrin receptor in non-Hodgkin's lymphoma. Lett. Pept. Sci. 8 (2002), 171–178.
146. Soodgupta, D., Zhou, H., Beaino, W., Lu, L., Snee, M., Skeath, J., DiPersio, J.F., Akers, W.J., Laforest, R., Anderson, C.J., Tomasson, M.H., Shokeen, M., Ex vivo and in vivo evaluation of over-expressed VLA-4 in multiple myeloma using LLP2A imaging agents. J. Nucl. Med. 57 (2016), 640–645.
147. Beaino, W., Anderson, C.J., PET imaging of very late antigen-4 in melanoma: comparison of 68Ga- and 64Cu-labeled NODAGA and CB-TE1A1P-LLP2A conjugates. J. Nucl. Med. 55 (2014), 1856–1863.
148. Beaino, W., Nedrow, J.R., Anderson, C.J., Evaluation of (68)Ga- and (177)Lu-DOTA-PEG4-LLP2A for VLA-4-targeted PET imaging and treatment of metastatic melanoma. Mol. Pharm. 12 (2015), 1929–1938.
149. Denardo, S.J., Liu, R., Albrecht, H., Natarajan, A., Sutcliffe, J.L., Anderson, C., Peng, L., Ferdani, R., Cherry, S.R., Lam, K.S., 111In-LLP2A-DOTA polyethylene glycol-targeting {alpha}4{beta}1 integrin: comparative pharmacokinetics for imaging and therapy of lymphoid malignancies. J. Nucl. Med. 50 (2009), 625–634.
150. Peng, L., Liu, R., Andrei, M., Xiao, W., Lam, K.S., In vivo optical imaging of human lymphoma xenograft using a library-derived peptidomimetic against alpha4beta1 integrin. Mol. Cancer Ther. 7 (2008), 432–437.
151. Shokeen, M., Zheleznyak, A., Wilson, J.M., Jiang, M., Liu, R., Ferdani, R., Lam, K.S., Schwarz, J.K., Anderson, C.J., Molecular imaging of very late antigen-4 (alpha4beta1 integrin) in the premetastatic niche. J. Nucl. Med. 53 (2012), 779–786.
152. Soodgupta, D., Hurchla, M.A., Jiang, M., Zheleznyak, A., Weilbaecher, K.N., Anderson, C.J., Tomasson, M.H., Shokeen, M., Very late antigen-4 (alpha(4)beta(1) integrin) targeted PET imaging of multiple myeloma. PLoS One, 8, 2013, e55841.
153. Zwingenberger, A.L., Kent, M.S., Liu, R., Kukis, D.L., Wisner, E.R., DeNardo, S.J., Taylor, S.L., Chen, X., Lam, K.S., In-vivo biodistribution and safety of 99mTc-LLP2A-HYNIC in canine non-Hodgkin lymphoma. PLoS One, 7, 2012, e34404.
154. Zwingenberger, A.L., Kent, M.S., Shi, C., Taylor, S.L., Chen, X., Lam, K.S., Affinity of the alpha4-beta1 integrin-targeting peptide LLP2A to canine lymphoma. Vet. Immunol. Immunopathol. 145 (2012), 298–304.
155. Xiao, W., Wang, Y., Lau, E.Y., Luo, J., Yao, N., Shi, C., Meza, L., Tseng, H., Maeda, Y., Kumaresan, P., Liu, R., Lightstone, F.C., Takada, Y., Lam, K.S., The use of one-bead one-compound combinatorial library technology to discover high-affinity alphavbeta3 integrin and cancer targeting arginine-glycine-aspartic acid ligands with a built-in handle. Mol. Cancer Ther. 9 (2010), 2714–2723.
156. Paez-Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, H., Vinals, F., Inoue, M., Bergers, G., Hanahan, D., Casanovas, O., Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15 (2009), 220–231.
157. Ebos, J.M., Lee, C.R., Cruz-Munoz, W., Bjarnason, G.A., Christensen, J.G., Kerbel, R.S., Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15 (2009), 232–239.
158. Kiessling, F., Huppert, J., Zhang, C., Jayapaul, J., Zwick, S., Woenne, E.C., Mueller, M.M., Zentgraf, H., Eisenhut, M., Addadi, Y., Neeman, M., Semmler, W., RGD-labeled USPIO inhibits adhesion and endocytotic activity of alpha v beta3-integrin-expressing glioma cells and only accumulates in the vascular tumor compartment. Radiology 253 (2009), 462–469.
159. Reynolds, A.R., Hart, I.R., Watson, A.R., Welti, J.C., Silva, R.G., Robinson, S.D., Da Violante, G., Gourlaouen, M., Salih, M., Jones, M.C., Jones, D.T., Saunders, G., Kostourou, V., Perron-Sierra, F., Norman, J.C., Tucker, G.C., Hodivala-Dilke, K.M., Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat. Med. 15 (2009), 392–400.
160. Cho, C.F., Amadei, G.A., Breadner, D., Luyt, L.G., Lewis, J.D., Discovery of novel integrin ligands from combinatorial libraries using a multiplex “beads on a bead” approach. Nano Lett. 12 (2012), 5957–5965.
161. Wong, A.H., Zhou, D., Rini, J.M., The X-ray crystal structure of human aminopeptidase N reveals a novel dimer and the basis for peptide processing. J. Biol. Chem. 287 (2012), 36804–36813.
162. Wang, W., Wei, Z., Zhang, D., Ma, H., Wang, Z., Bu, X., Li, M., Geng, L., Lausted, C., Hood, L., Fang, Q., Wang, H., Hu, Z., Rapid screening of peptide probes through in situ single-bead sequencing microarray. Anal. Chem. 86 (2014), 11854–11859.
163. Ding, H., Prodinger, W.M., Kopecek, J., Two-step fluorescence screening of CD21-binding peptides with one-bead one-compound library and investigation of binding properties of N-(2-hydroxypropyl)methacrylamide copolymer–peptide conjugates. Biomacromolecules 7 (2006), 3037–3046.
164. Winssinger, N., Damoiseaux, R., Tully, D.C., Geierstanger, B.H., Burdick, K., Harris, J.L., PNA-encoded protease substrate microarrays. Chem. Biol. 11 (2004), 1351–1360.
165. Zambaldo, C., Barluenga, S., Winssinger, N., PNA-encoded chemical libraries. Curr. Opin. Chem. Biol. 26 (2015), 8–15.
166. Svensen, N., Diaz-Mochon, J.J., Bradley, M., Decoding a PNA encoded peptide library by PCR: the discovery of new cell surface receptor ligands. Chem. Biol. 18 (2011), 1284–1289.
167. Svensen, N., Diaz-Mochon, J.J., Bradley, M., Encoded peptide libraries and the discovery of new cell binding ligands. Chem. Commun. (Camb.) 47 (2011), 7638–7640.
168. Thapa, P., Zhang, R.Y., Menon, V., Bingham, J.P., Native chemical ligation: a boon to peptide chemistry. Molecules 19 (2014), 14461–14483.
169. Xu, Q., Lam, K.S., Protein and chemical microarrays—powerful tools for proteomics. J. Biomed. Biotechnol. 2003 (2003), 257–266.
170. Ding, Y., Li, J., Xiao, W., Xiao, K., Lee, J., Bhardwaj, U., Zhu, Z., Digiglio, P., Yang, G., Lam, K.S., Pan, T., Microfluidic-enabled print-to-screen platform for high-throughput screening of combinatorial chemotherapy. Anal. Chem. 87 (2015), 10166–10171.
171. Ding, Y., Huang, E., Lam, K.S., Pan, T., Microfluidic impact printer with interchangeable cartridges for versatile non-contact multiplexed micropatterning. Lab Chip 13 (2013), 1902–1910.
172. Marr, A., Nissen, F., Maisch, D., Altmann, A., Rana, S., Debus, J., Huber, P.E., Haberkorn, U., Askoxylakis, V., Peptide arrays for development of PDGFRbeta affine molecules. Mol. Imaging Biol. 15 (2013), 391–400.
173. Guan, M., Yao, W., Liu, R., Lam, K.S., Nolta, J., Jia, J., Panganiban, B., Meng, L., Zhou, P., Shahnazari, M., Ritchie, R.O., Lane, N.E., Directing mesenchymal stem cells to bone to augment bone formation and increase bone mass. Nat. Med. 18 (2012), 456–462.
174. Zhu, D., Qin, Y., Wang, J., Zhang, L., Zou, S., Zhu, X., Zhu, L., Novel glypican-3-binding peptide for in vivo hepatocellular carcinoma fluorescent imaging. Bioconjug. Chem. 27 (2016), 831–839.
175. Chang, H.N., Liu, B.Y., Qi, Y.K., Zhou, Y., Chen, Y.P., Pan, K.M., Li, W.W., Zhou, X.M., Ma, W.W., Fu, C.Y., Qi, Y.M., Liu, L., Gao, Y.F., Blocking of the PD-1/PD-L1 interaction by a D-peptide antagonist for cancer immunotherapy. Angew. Chem. Int. Ed. Eng. 54 (2015), 11760–11764.
176. Bertoldo, D., Khan, M.M., Dessen, P., Held, W., Huelsken, J., Heinis, C., Phage selection of peptide macrocycles against beta-catenin to interfere with Wnt signaling. ChemMedChem 11 (2016), 834–839.
177. Cho, J.H., Ha, N.R., Koh, S.H., Yoon, M.Y., Design of a PKCdelta-specific small peptide as a theragnostic agent for glioblastoma. Anal. Biochem. 496 (2016), 63–70.
178. Qin, X., Zhang, C., Xue, X., Li, M., Li, W., Hao, Q., Zhang, Y., Yan, Z., Wei, Z., Identification of a novel peptide ligand of human transferrin receptor 1 for targeted tumor delivery drug. Protein Pept. Lett. 20 (2013), 96–101.
179. Mai, J., Song, S., Rui, M., Liu, D., Ding, Q., Peng, J., Xu, Y., A synthetic peptide mediated active targeting of cisplatin liposomes to Tie2 expressing cells. J. Control. Release 139 (2009), 174–181.
180. Ding, H., Prodinger, W.M., Kopecek, J., Identification of CD21-binding peptides with phage display and investigation of binding properties of HPMA copolymer–peptide conjugates. Bioconjug. Chem. 17 (2006), 514–523.
181. El-Mousawi, M., Tchistiakova, L., Yurchenko, L., Pietrzynski, G., Moreno, M., Stanimirovic, D., Ahmad, D., Alakhov, V., A vascular endothelial growth factor high affinity receptor 1-specific peptide with antiangiogenic activity identified using a phage display peptide library. J. Biol. Chem. 278 (2003), 46681–46691.
182. Naiyer, M.M., Saha, S., Hemke, V., Roy, S., Singh, S., Musti, K.V., Saha, B., Identification and characterization of a human IL-10 receptor antagonist. Hum. Immunol. 74 (2013), 28–31.
183. Song, S., Liu, D., Peng, J., Sun, Y., Li, Z., Gu, J.R., Xu, Y., Peptide ligand-mediated liposome distribution and targeting to EGFR expressing tumor in vivo. Int. J. Pharm. 363 (2008), 155–161.
184. Dejesus, O.T., Synthesis of [64Cu]Cu-NOTA-Bn-GE11 for PET imaging of EGFR-rich tumors. Curr. Radiopharm. 5 (2012), 15–18.
185. Cheng, Y., Meyers, J.D., Agnes, R.S., Doane, T.L., Kenney, M.E., Broome, A.M., Burda, C., Basilion, J.P., Addressing brain tumors with targeted gold nanoparticles: a new gold standard for hydrophobic drug delivery?. Small 7 (2011), 2301–2306.
186. Kohno, M., Horibe, T., Haramoto, M., Yano, Y., Ohara, K., Nakajima, O., Matsuzaki, K., Kawakami, K., A novel hybrid peptide targeting EGFR-expressing cancers. Eur. J. Cancer 47 (2011), 773–783.
187. Abourbeh, G., Shir, A., Mishani, E., Ogris, M., Rodl, W., Wagner, E., Levitzki, A., PolyIC GE11 polyplex inhibits EGFR-overexpressing tumors. IUBMB Life 64 (2012), 324–330.
188. Schafer, A., Pahnke, A., Schaffert, D., van Weerden, W.M., de Ridder, C.M., Rodl, W., Vetter, A., Spitzweg, C., Kraaij, R., Wagner, E., Ogris, M., Disconnecting the yin and yang relation of epidermal growth factor receptor (EGFR)-mediated delivery: a fully synthetic, EGFR-targeted gene transfer system avoiding receptor activation. Hum. Gene Ther. 22 (2011), 1463–1473.
189. Ohno, S., Takanashi, M., Sudo, K., Ueda, S., Ishikawa, A., Matsuyama, N., Fujita, K., Mizutani, T., Ohgi, T., Ochiya, T., Gotoh, N., Kuroda, M., Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells. Mol. Ther. 21 (2013), 185–191.
190. Navari, M., Zare, M., Javanmardi, M., Asadi-Ghalehni, M., Modjtahedi, H., Rasaee, M.J., Epitope mapping of epidermal growth factor receptor (EGFR) monoclonal antibody and induction of growth-inhibitory polyclonal antibodies by vaccination with EGFR mimotope. Immunopharmacol. Immunotoxicol. 36 (2014), 309–315.
191. Zhou, J., Joshi, B.P., Duan, X., Pant, A., Qiu, Z., Kuick, R., Owens, S.R., Wang, T.D., EGFR overexpressed in colonic neoplasia can be detected on wide-field endoscopic imaging. Clin. Transl. Gastroenterol., 6, 2015, e101.
192. Wang, W., Chen, X., Li, T., Li, Y., Wang, R., He, D., Luo, W., Li, X., Wu, X., Screening a phage display library for a novel FGF8b-binding peptide with anti-tumor effect on prostate cancer. Exp. Cell Res. 319 (2013), 1156–1164.
193. Dai, X., Cai, C., Xiao, F., Xiong, Y., Huang, Y., Zhang, Q., Xiang, Q., Lou, G., Lian, M., Su, Z., Zheng, Q., Identification of a novel aFGF-binding peptide with anti-tumor effect on breast cancer from phage display library. Biochem. Biophys. Res. Commun. 445 (2014), 795–801.
194. Wu, X.P., Yan, Q.X., Huang, Y.D., Huang, H.X., Su, Z.J., Xiao, J., Zeng, Y.Y., Wang, Y., Nie, C.J., Yang, Y.G., Li, X.K., Isolation of a novel basic FGF-binding peptide with potent antiangiogenetic activity. J. Cell. Mol. Med. 14 (2010), 351–356.
195. Su, J.L., Lai, K.P., Chen, C.A., Yang, C.Y., Chen, P.S., Chang, C.C., Chou, C.H., Hu, C.L., Kuo, M.L., Hsieh, C.Y., Wei, L.H., A novel peptide specifically binding to interleukin-6 receptor (gp80) inhibits angiogenesis and tumor growth. Cancer Res. 65 (2005), 4827–4835.
196. Koivunen, E., Gay, D.A., Ruoslahti, E., Selection of peptides binding to the alpha 5 beta 1 integrin from phage display library. J. Biol. Chem. 268 (1993), 20205–20210.
197. Koivunen, E., Wang, B., Ruoslahti, E., Isolation of a highly specific ligand for the alpha 5 beta 1 integrin from a phage display library. J. Cell Biol. 124 (1994), 373–380.
198. Murayama, O., Nishida, H., Sekiguchi, K., Novel peptide ligands for integrin alpha 6 beta 1 selected from a phage display library. J. Biochem. (Tokyo) 120 (1996), 445–451.
199. Arap, W., Pasqualini, R., Ruoslahti, E., Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279 (1998), 377–380.
200. Line, B.R., Mitra, A., Nan, A., Ghandehari, H., Targeting tumor angiogenesis: comparison of peptide and polymer–peptide conjugates. J. Nucl. Med. 46 (2005), 1552–1560.
201. Hajitou, A., Trepel, M., Lilley, C.E., Soghomonyan, S., Alauddin, M.M., Marini, F.C. 3rd, Restel, B.H., Ozawa, M.G., Moya, C.A., Rangel, R., Sun, Y., Zaoui, K., Schmidt, M., von Kalle, C., Weitzman, M.D., Gelovani, J.G., Pasqualini, R., Arap, W., A hybrid vector for ligand-directed tumor targeting and molecular imaging. Cell 125 (2006), 385–398.
202. Wang, H., Chen, K., Cai, W., Li, Z., He, L., Kashefi, A., Chen, X., Integrin-targeted imaging and therapy with RGD4C–TNF fusion protein. Mol. Cancer Ther. 7 (2008), 1044–1053.
203. Fueyo, J., Alemany, R., Gomez-Manzano, C., Fuller, G.N., Khan, A., Conrad, C.A., Liu, T.J., Jiang, H., Lemoine, M.G., Suzuki, K., Sawaya, R., Curiel, D.T., Yung, W.K., Lang, F.F., Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J. Natl. Cancer Inst. 95 (2003), 652–660.
204. Chen, K., Chen, X., Integrin targeted delivery of chemotherapeutics. Theranostics 1 (2011), 189–200.
205. Pameijer, C.R., Navanjo, A., Meechoovet, B., Wagner, J.R., Aguilar, B., Wright, C.L., Chang, W.C., Brown, C.E., Jensen, M.C., Conversion of a tumor-binding peptide identified by phage display to a functional chimeric T cell antigen receptor. Cancer Gene Ther. 14 (2007), 91–97.
206. Koivunen, E., Arap, W., Valtanen, H., Rainisalo, A., Medina, O.P., Heikkila, P., Kantor, C., Gahmberg, C.G., Salo, T., Konttinen, Y.T., Sorsa, T., Ruoslahti, E., Pasqualini, R., Tumor targeting with a selective gelatinase inhibitor. Nat. Biotechnol. 17 (1999), 768–774.
207. Medina, O.P., Kairemo, K., Valtanen, H., Kangasniemi, A., Kaukinen, S., Ahonen, I., Permi, P., Annila, A., Sneck, M., Holopainen, J.M., Karonen, S.L., Kinnunen, P.K., Koivunen, E., Radionuclide imaging of tumor xenografts in mice using a gelatinase-targeting peptide. Anticancer Res. 25 (2005), 33–42.
208. Sprague, J.E., Li, W.P., Liang, K., Achilefu, S., Anderson, C.J., In vitro and in vivo investigation of matrix metalloproteinase expression in metastatic tumor models. Nucl. Med. Biol. 33 (2006), 227–237.
209. Robinson, P., Stuber, D., Deryckere, F., Tedbury, P., Lagrange, M., Orfanoudakis, G., Identification using phage display of peptides promoting targeting and internalization into HPV-transformed cell lines. J. Mol. Recognit. 18 (2005), 175–182.
210. Karmali, P.P., Kotamraju, V.R., Kastantin, M., Black, M., Missirlis, D., Tirrell, M., Ruoslahti, E., Targeting of albumin-embedded paclitaxel nanoparticles to tumors. Nanomedicine 5 (2009), 73–82.
211. Zhang, F., Niu, G., Lin, X., Jacobson, O., Ma, Y., Eden, H.S., He, Y., Lu, G., Chen, X., Imaging tumor-induced sentinel lymph node lymphangiogenesis with LyP-1 peptide. Amino Acids 42 (2012), 2343–2351.
212. Medina, O.P., Soderlund, T., Laakkonen, L.J., Tuominen, E.K., Koivunen, E., Kinnunen, P.K., Binding of novel peptide inhibitors of type IV collagenases to phospholipid membranes and use in liposome targeting to tumor cells in vitro. Cancer Res. 61 (2001), 3978–3985.
213. Penate Medina, O., Haikola, M., Tahtinen, M., Simpura, I., Kaukinen, S., Valtanen, H., Zhu, Y., Kuosmanen, S., Cao, W., Reunanen, J., Nurminen, T., Saris, P.E., Smith-Jones, P., Bradbury, M., Larson, S., Kairemo, K., Liposomal tumor targeting in drug delivery utilizing MMP-2- and MMP-9-binding ligands. J. Drug Deliv., 2011, 2011, 160515.
214. Cai, J., Wei, R., Cheng, J., Preparation and characterization of a novel chimeric protein VEGI-CTT in Escherichia coli. J. Biomed. Biotechnol., 2008, 2008, 564969.
215. Zou, Y., Chen, Y., Jiang, Y., Gao, J., Gu, J., Targeting matrix metalloproteinases and endothelial cells with a fusion peptide against tumor. Cancer Res. 67 (2007), 7295–7300.
216. Heikkila, P., Suojanen, J., Pirila, E., Vaananen, A., Koivunen, E., Sorsa, T., Salo, T., Human tongue carcinoma growth is inhibited by selective antigelatinolytic peptides. Int. J. Cancer 118 (2006), 2202–2209.
217. Sun, J.M., Zhang, C., Li, X.N., Initial screening of binding-peptide of the cell surface marker CD133 of cancer stem cells. Beijing Da Xue Xue Bao 40 (2008), 476–479.
218. Devemy, E., Blaschuk, O.W., Identification of a novel N-cadherin antagonist. Peptides 29 (2008), 1853–1861.
219. Devemy, E., Blaschuk, O.W., Identification of a novel dual E- and N-cadherin antagonist. Peptides 30 (2009), 1539–1547.
220. Aggarwal, S., Singh, P., Topaloglu, O., Isaacs, J.T., Denmeade, S.R., A dimeric peptide that binds selectively to prostate-specific membrane antigen and inhibits its enzymatic activity. Cancer Res. 66 (2006), 9171–9177.
221. Shi, L.F., Wu, Y., Li, C.Y., Identification of high-affinity VEGFR3-binding peptides through a phage-displayed random peptide library. J. Gynecol. Oncol. 26 (2015), 327–335.
222. Yang, L., Jiang, H., Shi, B., Wang, H., Li, J., Wang, H., Yao, M., Li, Z., Identification and characterization of Ch806 mimotopes. Cancer Immunol. Immunother. 59 (2010), 1481–1487.
223. Askoxylakis, V., Garcia-Boy, R., Rana, S., Kramer, S., Hebling, U., Mier, W., Altmann, A., Markert, A., Debus, J., Haberkorn, U., A new peptide ligand for targeting human carbonic anhydrase IX, identified through the phage display technology. PLoS One, 5, 2010, e15962.
224. Koolpe, M., Dail, M., Pasquale, E.B., An ephrin mimetic peptide that selectively targets the EphA2 receptor. J. Biol. Chem. 277 (2002), 46974–46979.
225. Blackburn, W.H., Dickerson, E.B., Smith, M.H., McDonald, J.F., Lyon, L.A., Peptide-functionalized nanogels for targeted siRNA delivery. Bioconjug. Chem. 20 (2009), 960–968.
226. van Geer, M.A., Bakker, C.T., Koizumi, N., Mizuguchi, H., Wesseling, J.G., Oude Elferink, R.P., Bosma, P.J., Ephrin A2 receptor targeting does not increase adenoviral pancreatic cancer transduction in vivo. World J. Gastroenterol. 15 (2009), 2754–2762.
227. Wang, S., Noberini, R., Stebbins, J.L., Das, S., Zhang, Z., Wu, B., Mitra, S., Billet, S., Fernandez, A., Bhowmick, N.A., Kitada, S., Pasquale, E.B., Fisher, P.B., Pellecchia, M., Targeted delivery of paclitaxel to EphA2-expressing cancer cells. Clin. Cancer Res. 19 (2013), 128–137.
228. Scarberry, K.E., Dickerson, E.B., McDonald, J.F., Zhang, Z.J., Magnetic nanoparticle–peptide conjugates for in vitro and in vivo targeting and extraction of cancer cells. J. Am. Chem. Soc. 130 (2008), 10258–10262.
229. Scarberry, K.E., Mezencev, R., McDonald, J.F., Targeted removal of migratory tumor cells by functionalized magnetic nanoparticles impedes metastasis and tumor progression. Nanomedicine (London) 6 (2011), 69–78.
230. Koolpe, M., Burgess, R., Dail, M., Pasquale, E.B., EphB receptor-binding peptides identified by phage display enable design of an antagonist with ephrin-like affinity. J. Biol. Chem. 280 (2005), 17301–17311.
231. Xiong, C., Huang, M., Zhang, R., Song, S., Lu, W., Flores, L. 2nd, Gelovani, J., Li, C., In vivo small-animal PET/CT of EphB4 receptors using 64Cu-labeled peptide. J. Nucl. Med. 52 (2011), 241–248.
232. You, J., Zhang, R., Xiong, C., Zhong, M., Melancon, M., Gupta, S., Nick, A.M., Sood, A.K., Li, C., Effective photothermal chemotherapy using doxorubicin-loaded gold nanospheres that target EphB4 receptors in tumors. Cancer Res. 72 (2012), 4777–4786.
233. Thapa, N., Kim, S., So, I.S., Lee, B.H., Kwon, I.C., Choi, K., Kim, I.S., Discovery of a phosphatidylserine-recognizing peptide and its utility in molecular imaging of tumour apoptosis. J. Cell. Mol. Med. 12 (2008), 1649–1660.
234. Diderich, P., Heinis, C., Phage selection of bicyclic peptides binding Her2. Tetrahedron 70 (2014), 7733–7739.
235. Witsch, E.J., Mahlknecht, G., Wakim, J., Sertchook, R., Bublil, E., Yarden, Y., Sela, M., Generation and characterization of peptide mimotopes specific for anti ErbB-2 monoclonal antibodies. Int. Immunol. 23 (2011), 391–403.
236. Karasseva, N.G., Glinsky, V.V., Chen, N.X., Komatireddy, R., Quinn, T.P., Identification and characterization of peptides that bind human ErbB-2 selected from a bacteriophage display library. J. Protein Chem. 21 (2002), 287–296.
237. Kumar, S.R., Quinn, T.P., Deutscher, S.L., Evaluation of an 111In-radiolabeled peptide as a targeting and imaging agent for ErbB-2 receptor expressing breast carcinomas. Clin. Cancer Res. 13 (2007), 6070–6079.
238. Deutscher, S.L., Figueroa, S.D., Kumar, S.R., In-labeled KCCYSL peptide as an imaging probe for ErbB-2-expressing ovarian carcinomas. J. Label. Compd. Radiopharm. 52 (2009), 583–590.
239. Kumar, S.R., Gallazzi, F.A., Ferdani, R., Anderson, C.J., Quinn, T.P., Deutscher, S.L., In vitro and in vivo evaluation of (6)(4)Cu-radiolabeled KCCYSL peptides for targeting epidermal growth factor receptor-2 in breast carcinomas. Cancer Biother. Radiopharm. 25 (2010), 693–703.
240. Houimel, M., Schneider, P., Terskikh, A., Mach, J.P., Selection of peptides and synthesis of pentameric peptabody molecules reacting specifically with ErbB-2 receptor. Int. J. Cancer 92 (2001), 748–755.
241. Pero, S.C., Shukla, G.S., Armstrong, A.L., Peterson, D., Fuller, S.P., Godin, K., Kingsley-Richards, S.L., Weaver, D.L., Bond, J., Krag, D.N., Identification of a small peptide that inhibits the phosphorylation of ErbB2 and proliferation of ErbB2 overexpressing breast cancer cells. Int. J. Cancer 111 (2004), 951–960.
242. Shukla, G.S., Krag, D.N., Cancer cell-specific internalizing ligands from phage displayed beta-lactamase–peptide fusion libraries. Protein Eng. Des. Sel. 23 (2010), 431–440.
243. Rusckowski, M., Gupta, S., Liu, G., Dou, S., Hnatowich, D.J., Evidence of specificity of radiolabeled phage display peptides for the TAG-72 antigen. Cancer Biother. Radiopharm. 22 (2007), 564–572.
244. Chen, L., Wang, Y., Cheng, D., Dou, S., Liu, X., Liu, G., Hnatowich, D.J., Rusckowski, M., Comparing two TAG-72 binding peptides previously identified by phage display as potential imaging agents. Nucl. Med. Commun. 32 (2011), 920–924.
245. Xiao, N., Cheng, D., Wang, Y., Chen, L., Liu, X., Dou, S., Liu, G., Liang, M., Hnatowich, D.J., Rusckowski, M., Identification of a high affinity TAG-72 binding peptide by phage display selection. Cancer Biol. Ther. 11 (2011), 22–31.
246. Chen, L., Wang, Y., Liu, X., Dou, S., Liu, G., Hnatowich, D.J., Rusckowski, M., A new TAG-72 cancer marker peptide identified by phage display. Cancer Lett. 272 (2008), 122–132.
247. Zou, J., Glinsky, V.V., Landon, L.A., Matthews, L., Deutscher, S.L., Peptides specific to the galectin-3 carbohydrate recognition domain inhibit metastasis-associated cancer cell adhesion. Carcinogenesis 26 (2005), 309–318.
248. 111In-labeled galectin-3-targeting peptide as a SPECT agent for imaging breast tumors. J. Nucl. Med. 49 (2008), 796–803.
249. Deutscher, S.L., Figueroa, S.D., Kumar, S.R., Tumor targeting and SPECT imaging properties of an (111)In-labeled galectin-3 binding peptide in prostate carcinoma. Nucl. Med. Biol. 36 (2009), 137–146.
250. Landon, L.A., Peletskaya, E.N., Glinsky, V.V., Karasseva, N., Quinn, T.P., Deutscher, S.L., Combinatorial evolution of high-affinity peptides that bind to the Thomsen–Friedenreich carcinoma antigen. J. Protein Chem. 22 (2003), 193–204.
251. Landon, L.A., Zou, J., Deutscher, S.L., Effective combinatorial strategy to increase affinity of carbohydrate binding by peptides. Mol. Divers. 8 (2004), 35–50.
252. Kumar, S.R., Gallazzi, F.A., Quinn, T.P., Deutscher, S.L., (64)Cu-labeled peptide for PET of breast carcinomas expressing the Thomsen–Friedenreich carbohydrate antigen. J. Nucl. Med. 52 (2011), 1819–1826.
253. Peletskaya, E.N., Glinsky, V.V., Glinsky, G.V., Deutscher, S.L., Quinn, T.P., Characterization of peptides that bind the tumor-associated Thomsen–Friedenreich antigen selected from bacteriophage display libraries. J. Mol. Biol. 270 (1997), 374–384.
254. Pilch, J., Brown, D.M., Komatsu, M., Jarvinen, T.A., Yang, M., Peters, D., Hoffman, R.M., Ruoslahti, E., Peptides selected for binding to clotted plasma accumulate in tumor stroma and wounds. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 2800–2804.
255. Ballinger, M.D., Shyamala, V., Forrest, L.D., Deuter-Reinhard, M., Doyle, L.V., Wang, J.X., Panganiban-Lustan, L., Stratton, J.R., Apell, G., Winter, J.A., Doyle, M.V., Rosenberg, S., Kavanaugh, W.M., Semirational design of a potent, artificial agonist of fibroblast growth factor receptors. Nat. Biotechnol. 17 (1999), 1199–1204.
256. Maruta, F., Parker, A.L., Fisher, K.D., Hallissey, M.T., Ismail, T., Rowlands, D.C., Chandler, L.A., Kerr, D.J., Seymour, L.W., Identification of FGF receptor-binding peptides for cancer gene therapy. Cancer Gene Ther. 9 (2002), 543–552.
257. McConnell, S.J., Thon, V.J., Spinella, D.G., Isolation of fibroblast growth factor receptor binding sequences using evolved phage display libraries. Comb. Chem. High Throughput Screen. 2 (1999), 155–163.
258. Fukuda, M.N., Ohyama, C., Lowitz, K., Matsuo, O., Pasqualini, R., Ruoslahti, E., Fukuda, M., A peptide mimic of E-selectin ligand inhibits sialyl Lewis X-dependent lung colonization of tumor cells. Cancer Res. 60 (2000), 450–456.
259. Mueller, J., Gaertner, F.C., Blechert, B., Janssen, K.P., Essler, M., Targeting of tumor blood vessels: a phage-displayed tumor-homing peptide specifically binds to matrix metalloproteinase-2-processed collagen IV and blocks angiogenesis in vivo. Mol. Cancer Res. 7 (2009), 1078–1085.
260. Wu, P., Leinonen, J., Koivunen, E., Lankinen, H., Stenman, U.H., Identification of novel prostate-specific antigen-binding peptides modulating its enzyme activity. Eur. J. Biochem. 267 (2000), 6212–6220.
261. Urech-Varenne, C., Radtke, F., Heinis, C., Phage selection of bicyclic peptide ligands of the Notch1 receptor. ChemMedChem 10 (2015), 1754–1761.
262. Zhang, D., Jia, H., Li, W., Hou, Y., Lu, S., He, S., Screening and identification of a phage display derived peptide that specifically binds to the CD44 protein region encoded by variable exons. J. Biomol. Screen. 21 (2016), 44–53.
263. Zhang, D., Jia, H., Wang, Y., Li, W.M., Hou, Y.C., Yin, S.W., Wang, T.D., He, S.X., Lu, S.Y., A CD44 specific peptide developed by phage display for targeting gastric cancer. Biotechnol. Lett. 37 (2015), 2311–2320.
264. Wang, W., Chen, T., Li, H., Chen, Y., Wu, Z., Feng, T., Zhang, X., Zhong, Q., Zhong, Q., Li, G., Guo, L., Zhou, L., Zhou, J., Screening a novel FGF3 antagonist peptide with anti-tumor effects on breast cancer from a phage display library. Mol. Med. Rep. 12 (2015), 7051–7058.
265. Han, Z., Zhou, Z., Shi, X., Wang, J., Wu, X., Sun, D., Chen, Y., Zhu, H., Magi-Galluzzi, C., Lu, Z.R., EDB fibronectin specific peptide for prostate cancer targeting. Bioconjug. Chem. 26 (2015), 830–838.
266. He, X.Q., Guan, J., Liu, F., Li, J., He, M.R., Identification of the sAPRIL binding peptide and its growth inhibition effects in the colorectal cancer cells. PLoS One, 10, 2015, e0120564.
267. Khemthongcharoen, N., Ruangpracha, A., Sarapukdee, P., Rattanavarin, S., Jolivot, R., Jarujareet, U., Plaimas, K., Bhattarakosol, P., Patumraj, S., Piyawattanametha, W., Novel p16 binding peptide development for p16-overexpressing cancer cell detection using phage display. J. Pept. Sci. 21 (2015), 265–273.
268. Bose, D., Nahar, S., Rai, M.K., Ray, A., Chakraborty, K., Maiti, S., Selective inhibition of miR-21 by phage display screened peptide. Nucleic Acids Res. 43 (2015), 4342–4352.
269. Wang, X.F., Birringer, M., Dong, L.F., Veprek, P., Low, P., Swettenham, E., Stantic, M., Yuan, L.H., Zobalova, R., Wu, K., Ledvina, M., Ralph, S.J., Neuzil, J., A peptide conjugate of vitamin E succinate targets breast cancer cells with high ErbB2 expression. Cancer Res. 67 (2007), 3337–3344.
270. Shadidi, M., Sioud, M., Identification of novel carrier peptides for the specific delivery of therapeutics into cancer cells. FASEB J. 17 (2003), 256–258.
271. Luo, H., Yang, J., Jin, H., Huang, C., Fu, J., Yang, F., Gong, H., Zeng, S., Luo, Q., Zhang, Z., Tetrameric far-red fluorescent protein as a scaffold to assemble an octavalent peptide nanoprobe for enhanced tumor targeting and intracellular uptake in vivo. FASEB J. 25 (2011), 1865–1873.
272. Jie, L.Y., Cai, L.L., Wang, L.J., Ying, X.Y., Yu, R.S., Zhang, M.M., Du, Y.Z., Actively-targeted LTVSPWY peptide-modified magnetic nanoparticles for tumor imaging. Int. J. Nanomedicine 7 (2012), 3981–3989.
273. Orban, E., Manea, M., Marquadt, A., Banoczi, Z., Csik, G., Fellinger, E., Bosze, S., Hudecz, F., A new daunomycin–peptide conjugate: synthesis, characterization and the effect on the protein expression profile of HL-60 cells in vitro. Bioconjug. Chem. 22 (2011), 2154–2165.
274. Wu, C.H., Kuo, Y.H., Hong, R.L., Wu, H.C., alpha-Enolase-binding peptide enhances drug delivery efficiency and therapeutic efficacy against colorectal cancer. Sci. Transl. Med., 7, 2015 (290ra291).
275. Jeong, M.-H., Kim, K., Kim, E.-M., Cheong, S.-J., Lee, C.-M., Jeong, H.-J., Kim, D.W., Lim, S.T., Sohn, M.-H., Chung, J., In vivo and in vitro evaluation of Cy5.5 conjugated epidermal growth factor receptor binding peptide. Nucl. Med. Biol. 39 (2012), 805–812.
276. Staquicini, F.I., Tandle, A., Libutti, S.K., Sun, J., Zigler, M., Bar-Eli, M., Aliperti, F., Perez, E.C., Gershenwald, J.E., Mariano, M., Pasqualini, R., Arap, W., Lopes, J.D., A subset of host B lymphocytes controls melanoma metastasis through a melanoma cell adhesion molecule/MUC18-dependent interaction: evidence from mice and humans. Cancer Res. 68 (2008), 8419–8428.
277. Wang, T., D'Souza, G.G., Bedi, D., Fagbohun, O.A., Potturi, L.P., Papahadjopoulos-Sternberg, B., Petrenko, V.A., Torchilin, V.P., Enhanced binding and killing of target tumor cells by drug-loaded liposomes modified with tumor-specific phage fusion coat protein. Nanomedicine (London) 5 (2010), 563–574.
278. Fagbohun, O.A., Bedi, D., Grabchenko, N.I., Deinnocentes, P.A., Bird, R.C., Petrenko, V.A., Landscape phages and their fusion proteins targeted to breast cancer cells. Protein Eng. Des. Sel. 25 (2012), 271–283.
279. Wang, T., Petrenko, V.A., Torchilin, V.P., Paclitaxel-loaded polymeric micelles modified with MCF-7 cell-specific phage protein: enhanced binding to target cancer cells and increased cytotoxicity. Mol. Pharm. 7 (2010), 1007–1014.
280. Wu, C., Lo, S.L., Boulaire, J., Hong, M.L., Beh, H.M., Leung, D.S., Wang, S., A peptide-based carrier for intracellular delivery of proteins into malignant glial cells in vitro. J. Control. Release 130 (2008), 140–145.
281. Wang, C., Ning, L., Wang, H., Lu, Z., Li, X., Fan, X., Wang, X., Liu, Y., A peptide-mediated targeting gene delivery system for malignant glioma cells. Int. J. Nanomedicine 8 (2013), 3631–3640.
282. Kim, J.W., Kane, J.R., Young, J.S., Chang, A.L., Kanojia, D., Morshed, R.A., Miska, J., Ahmed, A.U., Balyasnikova, I.V., Han, Y., Zhang, L., Curiel, D.T., Lesniak, M.S., A genetically modified adenoviral vector with a phage display-derived peptide incorporated into fiber fibritin chimera prolongs survival in experimental glioma. Hum. Gene Ther. 26 (2015), 635–646.
283. Beck, S., Jin, X., Yin, J., Kim, S.H., Lee, N.K., Oh, S.Y., Jin, X., Kim, M.K., Kim, E.B., Son, J.S., Kim, S.C., Nam, D.H., Kim, S.H., Kang, S.K., Kim, H., Choi, Y.J., Identification of a peptide that interacts with Nestin protein expressed in brain cancer stem cells. Biomaterials 32 (2011), 8518–8528.
284. Matsuo, A.L., Tanaka, A.S., Juliano, M.A., Rodrigues, E.G., Travassos, L.R., A novel melanoma-targeting peptide screened by phage display exhibits antitumor activity. J. Mol. Med. (Berl.) 88 (2010), 1255–1264.
285. Kelly, K., Alencar, H., Funovics, M., Mahmood, U., Weissleder, R., Detection of invasive colon cancer using a novel, targeted, library-derived fluorescent peptide. Cancer Res. 64 (2004), 6247–6251.
286. Kelly, K.A., Jones, D.A., Isolation of a colon tumor specific binding peptide using phage display selection. Neoplasia 5 (2003), 437–444.
287. Huang, G., Zhang, C., Li, S., Khemtong, C., Yang, S.G., Tian, R., Minna, J.D., Brown, K.C., Gao, J., A novel strategy for surface modification of superparamagnetic iron oxide nanoparticles for lung cancer imaging. J. Mater. Chem. 19 (2009), 6367–6372.
288. Zhou, X., Chang, Y.C., Oyama, T., McGuire, M.J., Brown, K.C., Cell-specific delivery of a chemotherapeutic to lung cancer cells. J. Am. Chem. Soc. 126 (2004), 15656–15657.
289. Li, S., McGuire, M.J., Lin, M., Liu, Y.H., Oyama, T., Sun, X., Brown, K.C., Synthesis and characterization of a high-affinity {alpha}v{beta}6-specific ligand for in vitro and in vivo applications. Mol. Cancer Ther. 8 (2009), 1239–1249.
290. Li, S., Gray, B.P., McGuire, M.J., Brown, K.C., Synthesis and biological evaluation of a peptide–paclitaxel conjugate which targets the integrin alphavbeta(6). Bioorg. Med. Chem. 19 (2011), 5480–5489.
291. Guan, H., McGuire, M.J., Li, S., Brown, K.C., Peptide-targeted polyglutamic acid doxorubicin conjugates for the treatment of alpha(v)beta(6)-positive cancers. Bioconjug. Chem. 19 (2008), 1813–1821.
292. Guthi, J.S., Yang, S.G., Huang, G., Li, S., Khemtong, C., Kessinger, C.W., Peyton, M., Minna, J.D., Brown, K.C., Gao, J., MRI-visible micellar nanomedicine for targeted drug delivery to lung cancer cells. Mol. Pharm. 7 (2010), 32–40.
293. Gray, B.P., Li, S., Brown, K.C., From phage display to nanoparticle delivery: functionalizing liposomes with multivalent peptides improves targeting to a cancer biomarker. Bioconjug. Chem. 24 (2013), 85–96.
294. Tang, B., Li, Z., Huang, D., Zheng, L., Li, Q., Screening of a specific peptide binding to VPAC1 receptor from a phage display peptide library. PLoS One, 8, 2013, e54264.
295. Choi, J.H., Lee, W.K., Han, S.H., Ha, S., Ahn, S.M., Kang, J.S., Choi, Y.J., Yun, C.H., Identification and characterization of nonapeptide targeting a human B cell lymphoma, Raji. Int. Immunopharmacol. 8 (2008), 852–858.
296. Sun, X., Niu, G., Yan, Y., Yang, M., Chen, K., Ma, Y., Chan, N., Shen, B., Chen, X., Phage display-derived peptides for osteosarcoma imaging. Clin. Cancer Res. 16 (2010), 4268–4277.
297. Wang, D., Li, W., Zhang, H., Mao, Q., Xia, H., A targeting peptide improves adenovirus-mediated transduction of a glioblastoma cell line. Oncol. Rep. 31 (2014), 2093–2098.
298. Kim, Y., Lillo, A.M., Steiniger, S.C., Liu, Y., Ballatore, C., Anichini, A., Mortarini, R., Kaufmann, G.F., Zhou, B., Felding-Habermann, B., Janda, K.D., Targeting heat shock proteins on cancer cells: selection, characterization, and cell-penetrating properties of a peptidic GRP78 ligand. Biochemistry 45 (2006), 9434–9444.
299. Yoneda, Y., Steiniger, S.C., Capkova, K., Mee, J.M., Liu, Y., Kaufmann, G.F., Janda, K.D., A cell-penetrating peptidic GRP78 ligand for tumor cell-specific prodrug therapy. Bioorg. Med. Chem. Lett. 18 (2008), 1632–1636.
300. Kang, J., Zhao, G., Lin, T., Tang, S., Xu, G., Hu, S., Bi, Q., Guo, C., Sun, L., Han, S., Xu, Q., Nie, Y., Wang, B., Liang, S., Ding, J., Wu, K., A peptide derived from phage display library exhibits anti-tumor activity by targeting GRP78 in gastric cancer multidrug resistance cells. Cancer Lett. 339 (2013), 247–259.
301. Passarella, R.J., Spratt, D.E., van der Ende, A.E., Phillips, J.G., Wu, H., Sathiyakumar, V., Zhou, L., Hallahan, D.E., Harth, E., Diaz, R., Targeted nanoparticles that deliver a sustained, specific release of Paclitaxel to irradiated tumors. Cancer Res. 70 (2010), 4550–4559.
302. Essler, M., Ruoslahti, E., Molecular specialization of breast vasculature: a breast-homing phage-displayed peptide binds to aminopeptidase P in breast vasculature. Proc. Natl. Acad. Sci. U. S. A. 99 (2002), 2252–2257.
303. Arap, W., Kolonin, M.G., Trepel, M., Lahdenranta, J., Cardo-Vila, M., Giordano, R.J., Mintz, P.J., Ardelt, P.U., Yao, V.J., Vidal, C.I., Chen, L., Flamm, A., Valtanen, H., Weavind, L.M., Hicks, M.E., Pollock, R.E., Botz, G.H., Bucana, C.D., Koivunen, E., Cahill, D., Troncoso, P., Baggerly, K.A., Pentz, R.D., Do, K.A., Logothetis, C.J., Pasqualini, R., Steps toward mapping the human vasculature by phage display. Nat. Med. 8 (2002), 121–127.
304. Wang, W., Ke, S., Kwon, S., Yallampalli, S., Cameron, A.G., Adams, K.E., Mawad, M.E., Sevick-Muraca, E.M., A new optical and nuclear dual-labeled imaging agent targeting interleukin 11 receptor alpha-chain. Bioconjug. Chem. 18 (2007), 397–402.
305. Zurita, A.J., Troncoso, P., Cardo-Vila, M., Logothetis, C.J., Pasqualini, R., Arap, W., Combinatorial screenings in patients: the interleukin-11 receptor alpha as a candidate target in the progression of human prostate cancer. Cancer Res. 64 (2004), 435–439.
306. Joyce, J.A., Laakkonen, P., Bernasconi, M., Bergers, G., Ruoslahti, E., Hanahan, D., Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. Cancer Cell 4 (2003), 393–403.
307. Hamzah, J., Nelson, D., Moldenhauer, G., Arnold, B., Hammerling, G.J., Ganss, R., Vascular targeting of anti-CD40 antibodies and IL-2 into autochthonous tumors enhances immunotherapy in mice. J. Clin. Invest. 118 (2008), 1691–1699.
308. Pasqualini, R., Koivunen, E., Kain, R., Lahdenranta, J., Sakamoto, M., Stryhn, A., Ashmun, R.A., Shapiro, L.H., Arap, W., Ruoslahti, E., Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res. 60 (2000), 722–727.
309. Corti, A., Curnis, F., Arap, W., Pasqualini, R., The neovasculature homing motif NGR: more than meets the eye. Blood 112 (2008), 2628–2635.
310. Pastorino, F., Brignole, C., Marimpietri, D., Cilli, M., Gambini, C., Ribatti, D., Longhi, R., Allen, T.M., Corti, A., Ponzoni, M., Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res. 63 (2003), 7400–7409.
311. Pastorino, F., Di Paolo, D., Piccardi, F., Nico, B., Ribatti, D., Daga, A., Baio, G., Neumaier, C.E., Brignole, C., Loi, M., Marimpietri, D., Pagnan, G., Cilli, M., Lepekhin, E.A., Garde, S.V., Longhi, R., Corti, A., Allen, T.M., Wu, J.J., Ponzoni, M., Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin. Clin. Cancer Res. 14 (2008), 7320–7329.
312. Curnis, F., Sacchi, A., Borgna, L., Magni, F., Gasparri, A., Corti, A., Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat. Biotechnol. 18 (2000), 1185–1190.
313. Curnis, F., Sacchi, A., Corti, A., Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J. Clin. Invest. 110 (2002), 475–482.
314. Corti, A., Pastorino, F., Curnis, F., Arap, W., Ponzoni, M., Pasqualini, R., Targeted drug delivery and penetration into solid tumors. Med. Res. Rev. 32 (2012), 1078–1091.
315. Meng, J., Yan, Z., Wu, J., Li, L., Xue, X., Li, M., Li, W., Hao, Q., Wan, Y., Qin, X., Zhang, C., You, Y., Han, W., Zhang, Y., High-yield expression, purification and characterization of tumor-targeted IFN-alpha2a. Cytotherapy 9 (2007), 60–68.
316. Zhang, B., Gao, B., Dong, S., Zhang, Y., Wu, Y., Anti-tumor efficacy and pre-clinical immunogenicity of IFNalpha2a-NGR. Regul. Toxicol. Pharmacol. 60 (2011), 73–78.
317. Meng, J., Ma, N., Yan, Z., Han, W., Zhang, Y., NGR enhanced the anti-angiogenic activity of tum-5. J. Biochem. 140 (2006), 299–304.
318. Fogal, V., Zhang, L., Krajewski, S., Ruoslahti, E., Mitochondrial/cell-surface protein p32/gC1qR as a molecular target in tumor cells and tumor stroma. Cancer Res. 68 (2008), 7210–7218.
319. Laakkonen, P., Porkka, K., Hoffman, J.A., Ruoslahti, E., A tumor-homing peptide with a targeting specificity related to lymphatic vessels. Nat. Med. 8 (2002), 751–755.
320. Herringson, T.P., Altin, J.G., Effective tumor targeting and enhanced anti-tumor effect of liposomes engrafted with peptides specific for tumor lymphatics and vasculature. Int. J. Pharm. 411 (2011), 206–214.
321. Park, J.H., von Maltzahn, G., Xu, M.J., Fogal, V., Kotamraju, V.R., Ruoslahti, E., Bhatia, S.N., Sailor, M.J., Cooperative nanomaterial system to sensitize, target, and treat tumors. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 981–986.
322. Staquicini, F.I., Ozawa, M.G., Moya, C.A., Driessen, W.H., Barbu, E.M., Nishimori, H., Soghomonyan, S., Flores, L.G. 2nd, Liang, X., Paolillo, V., Alauddin, M.M., Basilion, J.P., Furnari, F.B., Bogler, O., Lang, F.F., Aldape, K.D., Fuller, G.N., Hook, M., Gelovani, J.G., Sidman, R.L., Cavenee, W.K., Pasqualini, R., Arap, W., Systemic combinatorial peptide selection yields a non-canonical iron-mimicry mechanism for targeting tumors in a mouse model of human glioblastoma. J. Clin. Invest. 121 (2011), 161–173.
323. Laakkonen, P., Akerman, M.E., Biliran, H., Yang, M., Ferrer, F., Karpanen, T., Hoffman, R.M., Ruoslahti, E., Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells. Proc. Natl. Acad. Sci. U. S. A. 101 (2004), 9381–9386.
324. Hariri, G., Yan, H., Wang, H., Han, Z., Hallahan, D.E., Radiation-guided drug delivery to mouse models of lung cancer. Clin. Cancer Res. 16 (2010), 4968–4977.
325. Han, Z., Fu, A., Wang, H., Diaz, R., Geng, L., Onishko, H., Hallahan, D.E., Noninvasive assessment of cancer response to therapy. Nat. Med. 14 (2008), 343–349.
326. Wang, H., Yan, H., Fu, A., Han, M., Hallahan, D., Han, Z., TIP-1 translocation onto the cell plasma membrane is a molecular biomarker of tumor response to ionizing radiation. PLoS One, 5, 2010, e12051.
327. Lowery, A., Onishko, H., Hallahan, D.E., Han, Z., Tumor-targeted delivery of liposome-encapsulated doxorubicin by use of a peptide that selectively binds to irradiated tumors. J. Control. Release 150 (2011), 117–124.
328. Hariri, G., Wellons, M.S., Morris, W.H. 3rd, Lukehart, C.M., Hallahan, D.E., Multifunctional FePt nanoparticles for radiation-guided targeting and imaging of cancer. Ann. Biomed. Eng. 39 (2011), 946–952.
329. Hallahan, D., Geng, L., Qu, S., Scarfone, C., Giorgio, T., Donnelly, E., Gao, X., Clanton, J., Integrin-mediated targeting of drug delivery to irradiated tumor blood vessels. Cancer Cell 3 (2003), 63–74.
330. Akita, N., Maruta, F., Seymour, L.W., Kerr, D.J., Parker, A.L., Asai, T., Oku, N., Nakayama, J., Miyagawa, S., Identification of oligopeptides binding to peritoneal tumors of gastric cancer. Cancer Sci. 97 (2006), 1075–1081.
331. Agemy, L., Friedmann-Morvinski, D., Kotamraju, V.R., Roth, L., Sugahara, K.N., Girard, O.M., Mattrey, R.F., Verma, I.M., Ruoslahti, E., Targeted nanoparticle enhanced proapoptotic peptide as potential therapy for glioblastoma. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 17450–17455.
332. Sugahara, K.N., Teesalu, T., Karmali, P.P., Kotamraju, V.R., Agemy, L., Greenwald, D.R., Ruoslahti, E., Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 328 (2010), 1031–1035.
333. Yan, Z., Yang, Y., Wei, X., Zhong, J., Wei, D., Liu, L., Xie, C., Wang, F., Zhang, L., Lu, W., He, D., Tumor-penetrating peptide mediation: an effective strategy for improving the transport of liposomes in tumor tissue. Mol. Pharm. 11 (2014), 218–225.
334. Mintz, P.J., Cardo-Vila, M., Ozawa, M.G., Hajitou, A., Rangel, R., Guzman-Rojas, L., Christianson, D.R., Arap, M.A., Giordano, R.J., Souza, G.R., Easley, J., Salameh, A., Oliviero, S., Brentani, R.R., Koivunen, E., Arap, W., Pasqualini, R., An unrecognized extracellular function for an intracellular adapter protein released from the cytoplasm into the tumor microenvironment. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 2182–2187.
335. Kelly, K.A., Bardeesy, N., Anbazhagan, R., Gurumurthy, S., Berger, J., Alencar, H., Depinho, R.A., Mahmood, U., Weissleder, R., Targeted nanoparticles for imaging incipient pancreatic ductal adenocarcinoma. PLoS Med., 5, 2008, e85.
336. Bausch, D., Thomas, S., Mino-Kenudson, M., Fernandez-del, C.C., Bauer, T.W., Williams, M., Warshaw, A.L., Thayer, S.P., Kelly, K.A., Plectin-1 as a novel biomarker for pancreatic cancer. Clin. Cancer Res. 17 (2011), 302–309.
337. Foight, G.W., Ryan, J.A., Gulla, S.V., Letai, A., Keating, A.E., Designed BH3 peptides with high affinity and specificity for targeting Mcl-1 in cells. ACS Chem. Biol. 9 (2014), 1962–1968.
338. Dutta, S., Gulla, S., Chen, T.S., Fire, E., Grant, R.A., Keating, A.E., Determinants of BH3 binding specificity for Mcl-1 versus BcI-x(L). J. Mol. Biol. 398 (2010), 747–762.
339. Kimura, R.H., Levin, A.M., Cochran, F.V., Cochran, J.R., Engineered cystine knot peptides that bind alphavbeta3, alphavbeta5, and alpha5beta1 integrins with low-nanomolar affinity. Proteins 77 (2009), 359–369.
340. Li, W.H., Lei, P., Yu, B., Wu, S., Peng, J.L., Zhao, X.P., Zhu, H.F., Kirschfink, M., Shen, G.X., Screening and identification of a novel target specific for hepatoma cell line HepG2 from the FliTrx bacterial peptide library. Acta Biochim. Biophys. Sin. 40 (2008), 443–451.
341. Zitzmann, S., Kramer, S., Mier, W., Mahmut, M., Fleig, J., Altmann, A., Eisenhut, M., Haberkorn, U., Identification of a new prostate-specific cyclic peptide with the bacterial FliTrx system. J. Nucl. Med. 46 (2005), 782–785.
342. Yang, W., Luo, D., Wang, S., Wang, R., Chen, R., Liu, Y., Zhu, T., Ma, X., Liu, R., Xu, G., Meng, L., Lu, Y., Zhou, J., Ma, D., TMTP1, a novel tumor-homing peptide specifically targeting metastasis. Clin. Cancer Res. 14 (2008), 5494–5502.
343. Dane, K.Y., Chan, L.A., Rice, J.J., Daugherty, P.S., Isolation of cell specific peptide ligands using fluorescent bacterial display libraries. J. Immunol. Methods 309 (2006), 120–129.
344. Dane, K.Y., Gottstein, C., Daugherty, P.S., Cell surface profiling with peptide libraries yields ligand arrays that classify breast tumor subtypes. Mol. Cancer Ther. 8 (2009), 1312–1318.
345. Brown, C.K., Modzelewski, R.A., Johnson, C.S., Wong, M.K., A novel approach for the identification of unique tumor vasculature binding peptides using an E. coli peptide display library. Ann. Surg. Oncol. 7 (2000), 743–749.
346. Dong, B., Wang, A.X., Yuan, L.H., Chen, L.S., Pu, K.F., Duan, W., Yan, X.Y., Zhu, Y.M., Peptide-fluorescent bacteria complex as luminescent reagents for cancer diagnosis. PLoS One, 8, 2013.
347. Hayashi, Y., Morimoto, J., Suga, H., In vitro selection of anti-Akt2 thioether-macrocyclic peptides leading to isoform-selective inhibitors. ACS Chem. Biol. 7 (2012), 607–613.
348. Morimoto, J., Hayashi, Y., Suga, H., Discovery of macrocyclic peptides armed with a mechanism-based warhead: isoform-selective inhibition of human deacetylase SIRT2. Angew. Chem. Int. Ed. Eng. 51 (2012), 3423–3427.
349. Lau, D., Guo, L., Liu, R., Marik, J., Lam, K., Peptide ligands targeting integrin alpha3beta1 in non-small cell lung cancer. Lung Cancer 52 (2006), 291–297.
350. Aina, O.H., Marik, J., Liu, R., Lau, D.H., Lam, K.S., Identification of novel targeting peptides for human ovarian cancer cells using “one-bead one-compound” combinatorial libraries. Mol. Cancer Ther. 4 (2005), 806–813.
351. Lau, D.H., Guo, L., Liu, R., Song, A., Shao, C., Lam, K.S., Identifying peptide ligands for cell surface receptors using cell-growth-on-bead assay and one-bead one-compound combinatorial library. Biotechnol. Lett. 24 (2002), 497–500.
352. DeRoock, I.B., Pennington, M.E., Sroka, T.C., Lam, K.S., Bowden, G.T., Bair, E.L., Cress, A.E., Synthetic peptides inhibit adhesion of human tumor cells to extracellular matrix proteins. Cancer Res. 1 (2001), 3308–3313.
353. Nair, R.R., Emmons, M.F., Cress, A.E., Argilagos, R.F., Lam, K., Kerr, W.T., Wang, H.G., Dalton, W.S., Hazlehurst, L.A., HYD1-induced increase in reactive oxygen species leads to autophagy and necrotic cell death in multiple myeloma cells. Mol. Cancer Ther. 8 (2009), 2441–2451.
354. Pennington, M.E., Lam, K.S., Cress, A.E., The use of a combinatorial library method to isolate human tumor cell adhesion peptides. Mol. Divers. 2 (1996), 19–28.
355. Aggarwal, S., Janssen, S., Wadkins, R.M., Harden, J.L., Denmeade, S.R., A combinatorial approach to the selective capture of circulating malignant epithelial cells by peptide ligands. Biomaterials 26 (2005), 6077–6086.
356. Lam, K.S., Lou, Q., Zhao, Z.G., Smith, J., Chen, M.L., Pleshko, E., Salmon, S.E., Idiotype specific peptides bind to the surface immunoglobulins of two murine B-cell lymphoma lines, inducing signal transduction. Biomed. Pept. Proteins Nucleic Acids 1 (1995), 205–210.
357. Mikawa, M., Wang, H., Guo, L., Liu, R., Marik, J., Takada, Y., Lam, K., Lau, D., Novel peptide ligands for integrin alpha 4 beta 1 overexpressed in cancer cells. Mol. Cancer Ther. 3 (2004), 1329–1334.
358. Liu, R., Peng, L., Han, H.J., Lam, K.S., Structure–activity relationship studies of a series of peptidomimetic ligands for alpha(4)beta(1) integrin on Jurkat T-leukemia cells. Biopolymers 84 (2006), 595–604.
359. Zhang, H., Aina, O.H., Lam, K.S., de Vere White, R., Evans, C., Henderson, P., Lara, P.N., Wang, X., Bassuk, J.A., Pan, C.X., Identification of a bladder cancer-specific ligand using a combinatorial chemistry approach. Urol. Oncol. 30 (2012), 635–645.
360. Lin, T.Y., Zhang, H., Wang, S., Xie, L., Li, B., Rodriguez, C.O. Jr., de Vere White, R., Pan, C.X., Targeting canine bladder transitional cell carcinoma with a human bladder cancer-specific ligand. Mol. Cancer, 10, 2011, 9.
361. Lin, T.Y., Zhang, H., Luo, J., Li, Y., Gao, T., Lara, P.N. Jr., de Vere White, R., Lam, K.S., Pan, C.X., Multifunctional targeting micelle nanocarriers with both imaging and therapeutic potential for bladder cancer. Int. J. Nanomedicine 7 (2012), 2793–2804.